Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.47 |
| ▸ | MAOB | P27338 | 3/20 | 0.47 |
| ▸ | KDM1A | O60341 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26620796 | 0.87 | MAOA (0.51) | MAOAMAOBKDM1AMEN1KMT2A | |
| SCHEMBL15456460 | 0.81 | MAOA (0.62) | MAOAMAOBKDM1AMEN1KMT2A | |
| SCHEMBL15456202 | 0.81 | MAOA (0.62) | MAOAMAOBKDM1AMEN1KMT2A | |
| SCHEMBL13276465 | 0.81 | MAOA (0.62) | MAOAMAOBKDM1AMEN1KMT2A | |
| SCHEMBL13276199 | 0.81 | MAOA (0.62) | MAOAMAOBKDM1AMEN1KMT2A | |
| SCHEMBL18920810 | 0.81 | MAOA (0.62) | MAOAMAOBKDM1AMEN1KMT2A | |
| SCHEMBL27010638 | 0.80 | MAOA (0.52) | MAOAMAOBKDM1AMEN1KMT2A | |
| SCHEMBL27010644 | 0.80 | IKZF2 (0.43) | MAOAKDM1AKMT2A | |
| SCHEMBL27010660 | 0.78 | HTT (0.42) | MAOAMAOBKDM1AMEN1KMT2A | |
| SCHEMBL27010666 | 0.78 | SMN1; SMN2 (0.41) | KMT2ACYP3A4MAPK1SMN1; SMN2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | MAOA 271/4885MAOB 283/4885KDM1A 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.